AIM
RNTX

Alerce Investment Management’s Rein Therapeutics RNTX Stock Holding History

Alerce Investment Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-830,466
Closed -$5.51M – 6
2024
Q1 		$5.51M Hold
830,466
– – 5.79% 4
2023
Q4 		$2.53M Hold
830,466
– – 3.37% 5
2023
Q3 		$1.26M Hold
830,466
– – 2.16% 6
2023
Q2 		$1.49M Hold
830,466
– – 1.93% 6
2023
Q1 		$1.03M Hold
830,466
– – 1.36% 6
2022
Q4 		$1.97M Sell
830,466
-6
-0% -$20 2.26% 6
2022
Q3 		$3.43M Hold
830,472
– – 3.31% 6
2022
Q2 		$4.32M Hold
830,472
– – 8.01% 5
2022
Q1 		$8.51M Hold
830,472
– – 14.42% 2
2021
Q4 		$9.35M Hold
830,472
– – 9.51% 4
2021
Q3 		$16.9M Hold
830,472
– – 11.6% 3
2021
Q2 		$20.8M Hold
830,472
– – 11.27% 3
2021
Q1 		$23.8M Buy
830,472
+450,000
+118% +$15.4M 10.51% 3
2020
Q4 		$7.91M Buy
+380,472
New +$9.51M 3.12% 5

Other funds holding RNTX

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Alerce Investment Management's RNTX Position: Q2 2024 in Review

Alerce Investment Management sold out of Rein Therapeutics (RNTX) in Q2 2024, closing a stake of 830,466 shares — an estimated $5.51M sold.

Alerce Investment Management first reported a position in RNTX in Q4 2020 and held it in 14 quarters. The position peaked at $23.8M in Q1 2021. 29 funds tracked by Wall St. Rank hold RNTX as of Q2 2024.

  • Alerce Investment Management reported no remaining Rein Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Alerce Investment Management sold 830,466 Rein Therapeutics shares in Q2 2024, an estimated $5.51M.
  • Alerce Investment Management first reported a position in Rein Therapeutics in Q4 2020 and held it in 14 quarters.
  • Alerce Investment Management's Rein Therapeutics position peaked at $23.8M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2024.

Based on Alerce Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.